The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease

Carboplatin plus nab-paclitaxel, as a first-line chemotherapy regimen for non-small cell lung cancer, showed favorable efficacy and safety in patients with preexisting interstitial lung disease. Abstract Background The optimal chemotherapy regimen for non-small cell lung cancer patients with interst...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2018-01, Vol.48 (1), p.89-93
Main Authors: Yasuda, Yuichiro, Hattori, Yoshihiro, Tohnai, Rie, Ito, Shoichi, Kawa, Yoshitaka, Kono, Yuko, Urata, Yoshiko, Nogami, Munenobu, Takenaka, Daisuke, Negoro, Shunichi, Satouchi, Miyako
Format: Article
Language:English
Subjects:
Adult
Aged
Albumins - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carboplatin - therapeutic use
Carcinoma, Non-Small-Cell Lung - complications
Carcinoma, Non-Small-Cell Lung - drug therapy
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Lung Diseases, Interstitial - chemically induced
Lung Diseases, Interstitial - complications
Lung Neoplasms - drug therapy
Male
Middle Aged
Nanoparticles - administration & dosage
Nanoparticles - therapeutic use
Paclitaxel - therapeutic use
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carboplatin plus nab-paclitaxel, as a first-line chemotherapy regimen for non-small cell lung cancer, showed favorable efficacy and safety in patients with preexisting interstitial lung disease. Abstract Background The optimal chemotherapy regimen for non-small cell lung cancer patients with interstitial lung disease is unclear. We therefore investigated the safety and efficacy of carboplatin plus nab-paclitaxel as a first-line regimen for non-small cell lung cancer in patients with interstitial lung disease. Methods We retrospectively reviewed advanced non-small cell lung cancer patients with interstitial lung disease who received carboplatin plus nab-paclitaxel as a first-line chemotherapy regimen at Hyogo Cancer Center between February 2013 and August 2016. interstitial lung disease was diagnosed according to the findings of pretreatment chest high-resolution computed tomography. Results Twelve patients were included (male, n = 11; female, n = 1). The overall response rate was 67% and the disease control rate was 100%. The median progression free survival was 5.1 months (95% CI: 2.9–8.3 months) and the median overall survival was 14.9 months (95% CI: 4.8–not reached). A chemotherapy-related acute exacerbation of interstitial lung disease was observed in one patient; the extent of this event was Grade 2. There were no treatment-related deaths. Conclusions Carboplatin plus nab-paclitaxel, as a first-line chemotherapy regimen for non-small cell lung cancer, showed favorable efficacy and safety in patients with preexisting interstitial lung disease.
ISSN:0368-2811
1465-3621
DOI:10.1093/jjco/hyx142